scholarly journals Transplantation of Mesenchymal Stem Cells in Treating Patients with Severe COVID-19: A Systematic Review and Meta-Analysis

2020 ◽  
Vol 5 (3) ◽  
Keyword(s):  
Stem Cells ◽  
Clinical Trials ◽  
Mesenchymal Stem Cells ◽  
Stem Cell ◽  
Bibliographic Databases ◽  
Human Mscs ◽  
Medical Subject Headings ◽  
Human Organ ◽  
Mesenchymal Stem Cell Transplantation ◽  
Meeting Abstract

The objective of the study is to perform a critical review, exploration, and strong summary of the roles of mesenchymal stem cell transplantation in treating various diseases, including COVID-19. A comprehensive search was carried out in mainstream bibliographic databases or Medical Subject Headings, including Scien Direct, PubMed, Scopus, ISI Web of Science, and websites of the news. The search was applied to the articles that were published between January 2020 and April 2020. Needed article information was extracted from each article by : 1) direct information including journal (research article, review article, meeting abstract, conference abstract, correspondence, author index, editorial board meeting abstract, discussion), book chapter, title, authors, abstract, full text documents of candidate studies, websites of the news, publishing year; 2) study period; 3) research (study) method used; 4) types of mesenchymal stem cells; and 5) types of human organ system disorder or disease studied. With strict literature search and screening processes, it yielded 6 articles from 76 articles of initial literature databases and websites of the news (January 2020 to April 2020). Anti-inflammatory and immunomodulatory properties of MSCs in the treatment of respiratory diseases were confirmed by at least 17 clinical studies and more than 70 clinical trials are registered in this issue that are available at: https:// www.clinicaltrials.gov. MSC transplantation improves the treatment outcome of COVID-19 patients may be due to controlling inflammatory response and promoting tissue regeneration and repair. In conclusion, Human MSCs are currently being evaluated as a stem cell treatment for a number of diseases, particularly severe COVID-19 and have been demonstrated to be safe in clinical trials. There are some promising reports to apply MSCs therapy to treat COVID-19. MSCs may possibly be one of the most ideal therapeutics, or a combination of treatment to treat patients with COVID-19. Nevertheless, further studies are urgently needed to investigate and optimize a number of variables in the human MSC culture environment by developing a bioprocess that can be operated in accordance with the Good Manufacturing Product (GMP).

scholarly journals Expanded mesenchymal stem cell transplantation is safe in both local injection and vein transfusion

2017 ◽  
Vol 4 (3-4) ◽  
pp. 234-235 ◽  
Author(s):  
Vlassov V Salval ◽  
Yone Moto
Keyword(s):  
Stem Cells ◽  
Clinical Trials ◽  
Stem Cell ◽  
Clinical Applications ◽  
Local Injection ◽  
Mesenchymal Stem Cell Transplantation ◽  
Routine Treatment ◽  
Drug Products ◽  
The World

More than 500 clinical trials are using mesenchymal stem cells (MSCs) in the world to treat some different diseases. The safety of expanded MSC transplantation is the most important thing to ensure that this therapy can become the routine treatment for human diseases. More than five MSCs based stem cell drug products are approved at various countries demonstrated that expanded MSCs are safe in both local injection and transfusion. Moreover, some recent reports for 5 and 10 years followed-up clinical trials using expanded MSCs confirmed that there is not different tumorigenesis between the patients with and without expanded MSC transplantation. This letter aims to provide some evidences about the safety of expanded MSCs in clinical applications. However, the MSC quality should be stritcly controlled during the in vitro MSC expansion.

A comprehensive cancer-associated microRNA expression profiling and proteomic analysis of human umbilical cord mesenchymal stem cell derived exosomes.

2021 ◽  
Author(s):  
Ganesan Jothimani ◽  
Surajait Pathak ◽  
Suman Dutta ◽  
Asim K. Duttaroy ◽  
Antara Banerjee
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Stem Cell ◽  
Growth Factors ◽  
Umbilical Cord ◽  
Expression Patterns ◽  
Functional Enrichment ◽  
Human Umbilical Cord ◽  
Human Mscs ◽  
Anti Cancer

Abstract Background The mesenchymal stem cells (MSCs) have enormous therapeutic potential owing to their multi-lineage differentiation and self-renewal properties. MSCs express growth factors, cytokines, chemokines, and non-coding regulatory RNAs with immunosuppressive, anti-tumor, and migratory properties. MSCs also release several anti-cancer molecules via extracellular vesicles, that act as pro-apoptotic/tumor suppressor factors. This study aimed to identify the stem cell-derived secretome that could exhibit anti-cancer properties through molecular profiling of cargos in MSC-derived exosomes. Methods Human umbilical cord mesenchymal stem cells (hUCMSCs) were isolated from umbilical cord tissues and cultured expanded. After that, exosomes were isolated from the hUCMSC conditioned medium. The miRNA profiling of hUCMSCs and hUCMSC-derived exosomes was performed, followed by functional enrichment analysis. Results The miRNA expression profile and gene ontology (GO) depicts the differential expression patterns of high and less-expressed miRNAs that are delineated to be involved in the regulation of the apoptosis process. The LCMS/MS data and GO analysis indicate that hUCMSC secretomes are involved in several oncogenic and inflammatory signaling cascades. Conclusion Primary human MSCs releases miRNAs and growth factors via exosomes that are increasingly implicated in intercellular communications, and hUCMSC-exosomal miRNAs may have a critical influence in regulating cell death and apoptosis of cancer cells.

scholarly journals Exercise as an Adjuvant to Bone and Cartilage Regeneration Therapy

2020 ◽  
Author(s):  
John Smith
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Stem Cell ◽  
Physical Exercise ◽  
Transforming Growth Factor ◽  
Immune Cell ◽  
Osteogenic Potential ◽  
Cell Transplant ◽  
Mesenchymal Stem Cell Transplantation ◽  
Micro Rnas

Abstract: This article provides a brief review of the ontogeny of chondrocytes and the pathophysiology of osteoarthritis (OA), and details how physical exercise improves the health of osteoarthritic joints and enhances the potential of mesenchymal stem cells for successful transplantation therapy. In response to exercise chondrocytes increase their production of glycosaminoglycans, bone morphogenic proteins and antiinflammatory cytokines and decrease their production of proinflammatory cytokines and matrix degrading metalloproteinases. These changes are associated with improvements in cartilage organization and reductions in cartilage degeneration. Studies in humans indicate that exercise increases peripheral blood recruitment of bone marrow-derived mesenchymal stem cells (BM-MSC) and upregulates BM-MSC expression of osteogenic and chondrogenic genes, osteogenic micro-RNAs, and osteogenic growth factors. Rodent experiments are uniform in demonstrating that exercise enhances the osteogenic potential of BM-MSC while diminishing their adipogenic potential, and that exercise done after stem cell implantation may benefit stem cell transplant viability. Physical exercise also exerts a beneficial effect on the skeletal system by decreasing immune cell production of osteoclastogenic cytokines interleukin (IL)-1β, tumor necrosis factor (TNF)-α, and interferon (INF)-γ while increasing their production anti-osteoclastogenic cytokines IL-10 and transforming growth factor (TGF)-β. In conclusion, physical exercise done both by stem cell donors and recipients may improve the outcome of mesenchymal stem cell transplantation.

scholarly journals A comparative study of mesenchymal stem cell transplantation and NTG-101 molecular therapy to treat degenerative disc disease

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Ajay Matta ◽  
Muhammad Zia Karim ◽  
Hoda Gerami ◽  
Bettina Benigno ◽  
W. Mark Erwin
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Degenerative Disc Disease ◽  
Molecular Therapy ◽  
Disc Disease ◽  
Mesenchymal Stem Cell Transplantation ◽  
Degenerative Disc

AbstractCellular replacement therapy using mesenchymal stem cells (MSCs) and/or the delivery of growth factors are at the forefront of minimally invasive biological treatment options for Degenerative Disc Disease (DDD). In this study, we compared the therapeutic potential of a novel drug candidate, NTG-101 to MSCs, including rat cartilage derived stem cells (rCDSCs), bone marrow stem cells (rBMSCs) and human Umbilical Cord Derived Mesenchymal Stem Cells (hUCMSCs) for the treatment of DDD. We induced DDD using a validated image-guided needle puncture injury in rat-tail IVDs. Ten weeks post-injury, animals were randomized and injected with MSCs, NTG-101 or vehicle. At the end of the study, histological analysis of the IVD-Nucleus Pulposus (NPs) injected with NTG-101 or rCDSCs showed a healthy or mild degenerative phenotype in comparison to vehicle controls. Immunohistochemical analysis revealed strong expression of aggrecan, collagen 2, brachyury and Oct4 in IVD-NPs injected with NTG-101. Our results also demonstrated suppression of inflammation induced p38 and NFκB resulting in inhibition of catabolic genes, but activation of Smad-2/3, Erk-1/2 and Akt-dependent signaling inducing anabolic genes in IVD-NP on treatment with NTG-101. In conclusion, a single injection of NTG-101 into the degenerative disc demonstrated superior benefits compared to stem cell transplantation.

scholarly journals Bone Regenerative Potential of Mesenchymal Stem Cells on a Micro- Structured Titanium Processed by Wire-Type Electric Discharge Machining

2010 ◽  
Vol 4 (1) ◽  
pp. 113-116 ◽  
Author(s):  
Yukimichi Tamaki ◽  
Yu Kataoka ◽  
In-Kee Jang ◽  
Takashi Miyazaki
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Electric Discharge ◽  
Functional Restoration ◽  
Titanium Implants ◽  
Electric Discharge Machining ◽  
Mesenchymal Stem Cell Transplantation ◽  
Scaffold Properties

A new strategy with bone tissue engineering by mesenchymal stem cell transplantation on titanium implant has been drawn attention. The surface scaffold properties of titanium surface play an important role in bone regenerative potential of cells. The surface topography and chemistry are postulated to be two major factors increasing the scaffold properties of titanium implants. This study aimed to evaluate the osteogenic gene expression of mesenchymal stem cells on titanium processed by wire-type electric discharge machining. Some amount of roughness and distinctive irregular features was observed on titanium processed by wire-type electric discharge machining. The thickness of suboxide layer was concomitantly grown during the processing. Since the thickness of oxide film and micro-topography allowed an improvement of mRNA expression of cells, titanium processed by wire-type electric discharge machining is a promising candidate for mesenchymal stem cell based functional restoration of implants.

Preclinical Safety Evaluation of Human Mesenchymal Stem Cell Transplantation in Cerebrum of Nonhuman Primates

2014 ◽  
Vol 33 (5) ◽  
pp. 403-411 ◽  
Author(s):  
Ming Feng ◽  
Yan Li ◽  
Qin Han ◽  
Xinjie Bao ◽  
Ming Yang ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Clinical Application ◽  
Low Dose ◽  
Human Mesenchymal Stem Cells ◽  
High Dose ◽  
Mesenchymal Stem Cell Transplantation

The efficacy of stem cell transplantation for promoting recovery of patients with neurological diseases, such as stroke, has been reported in several studies. However, the safety of the intracerebral transplantation of human mesenchymal stem cells (hMSCs) remains unclear. The aim of the study was to evaluate the safety of hMSCs transplanted in cerebrum of Macaca fascicularis and to provide evidence for clinical application. A total of 24 M fascicularis were assigned to 3 groups randomly: low dose (3.0 × 105 cells/kg), high dose (2.5 × 106 cells/kg), and the control (normal saline [NS]). Human mesenchymal stem cells or NS were injected into each monkey for 2 times, with an interval of 3 weeks. The injection point was located outside of the right putamen, according to a stereotactic map and preoperative magnetic resonance imaging of the monkeys. Animal health, behavior, biophysical and biochemical parameters, and brain neurological function were routinely monitored over a 6-month period posttransplantation, and the histopathologic examinations were also performed. The results showed that local pathologic damage including local tissue necrosis and inflammation was induced after the injection. The damage of low-dose and high-dose groups was greater than that of the control group, yet over time, the damage could be repaired gradually. No major hMSCs-associated changes were induced from other indicators, and the transplantation of hMSCs in monkeys did not affect total immunoglobulin (Ig) M, total IgG, CD3, CD4, or CD8 values. We therefore conclude that transplantation of hMSCs to the cerebrum represents a safe alternative for clinical application of neurological disorders.

scholarly journals MESENCHYMAL STEM CELL-BASED THERAPY FOR CHRONIC KIDNEY FAILURE RELATING LUPUS ERYTHEMATOSUS - A CASE REPORT

2021 ◽  
Vol 506 (1-2) ◽  
Author(s):  
Nguyen Duy Thang ◽  
Phan Thi Thuy Hoa ◽  
Phan Thi Dieu Ngan ◽  
Ngo Nhat Hoang ◽  
Che Thi Cam Ha
Keyword(s):  
Chronic Kidney Disease ◽  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Stem Cell ◽  
Kidney Disease ◽  
Mesenchymal Stem Cell ◽  
Lupus Erythematosus ◽  
Cellular Interactions ◽  
Mesenchymal Stem Cell Transplantation ◽  
Cell Based Therapy

Systemic lupus erythematosus (SLE) is a systemic autoimmune disease, which is characterized by systemic multiple-organ involvement, relapses with large amount of autoantibodies. Their pathophysiology is multifaceted, involves complex hormonal-immunological-cellular interactions, and leads to damage in multiple cell types, which is often resistant to conventional therapy. Thus, novel strategies are needed to repair the renal parenchyma and preserve kidney function. Mesenchymal stem cells (MSC) confer renal protection through paracrine/endocrine effects, and to some degree possibly by direct engraftment. The patient was diagnosed with chronic kidney disease by standard methods for more than fifteen years. The patient agreed to the treatment of autologous adipose mesenchymal stem cell transplantation. The adipose mesenchymal stem cells were harvested by surgery, isolated with our enzyme protocol. The patient received one injection with 2,6x106 cells/kg for a total of 43kg of body weight. The patient with SLE do not receive prompt treatment, he get irreversible organ damage. After seven months, the preexisting renal insufficiency gradually ameliorated, including the decrease of creatinine and blood urea as well as the increase of estimated glomerular filtration rate. Lupus symptoms also reduced, followed by the improvement of body movement and medication reduction.There was insufficient evidence of the clinical setting to show the efficiency of mesenchymal stem cells on the lupus nephritis relating to chronic kidney disease.  This clinical trial highlights the feasibility and safety of mesenchymal stem cell treatments in renal failure-associated- autoimmune diseases.

scholarly journals The Application of Mesenchymal Stem Cells in the Treatment of Liver Diseases: Mechanism, Efficacy, and Safety Issues

2021 ◽  
Vol 8 ◽  
Author(s):  
Ya Yang ◽  
Yalei Zhao ◽  
Lingjian Zhang ◽  
Fen Zhang ◽  
Lanjuan Li
Keyword(s):  
Stem Cells ◽  
Clinical Trials ◽  
Mesenchymal Stem Cells ◽  
Stem Cell ◽  
Immune Regulation ◽  
Liver Diseases ◽  
Efficacy And Safety ◽  
Safety Issues ◽  
Novel Treatment ◽  
Significant Efficacy

Mesenchymal stem cell (MSC) transplantation is a novel treatment for liver diseases due to the roles of MSCs in regeneration, fibrosis inhibition and immune regulation. However, the mechanisms are still not completely understood. Despite the significant efficacy of MSC therapy in animal models and preliminary clinical trials, issues remain. The efficacy and safety of MSC-based therapy in the treatment of liver diseases remains a challenging issue that requires more investigation. This article reviews recent studies on the mechanisms of MSCs in liver diseases and the associated challenges and suggests potential future applications.

Abstract 16769: Intravenous Injection of Neonatal Cardiac Mesenchymal Stem Cells is a Viable Alternative Route to Treat Acute Myocardial Infarction

Circulation ◽  
2020 ◽  
Vol 142 (Suppl_3) ◽  
Author(s):  
Progyaparamita Saha ◽  
Rachana Mishra ◽  
Sudhish Sharma ◽  
Aakash Shah ◽  
Lauren Davidson ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Stem Cells ◽  
Clinical Trials ◽  
Mesenchymal Stem Cells ◽  
Stem Cell ◽  
Placebo Group ◽  
Randomized Clinical Trials ◽  
Brown Norway ◽  
Male Rat ◽  
Myocardial Infraction

Introduction: Cardiovascular disease is major cause of morbidity and mortality around the world and major health care burden indeed. Ischemic heart disease (IHD) and myocardial ischemia (MI) are most devastating cardiovascular disease. Multiple stem cell/ cardiac progenitor cell therapy has been reported previously to treat cardiovascular disease safely. However randomized clinical trials with adult cardiac progenitor cells or cardiosphere-derived cells unable to show long-term efficacy. We have our unique source of human neonatal cardiac tissue derived neonatal cardiac mesenchymal stem cells (nMSCs). Systemic administration is preferred route of stem cell delivery in order to consecutive dosage for most of the clinical trials. We hypothesized that nMSCs have unique proteome profile, which supports their survival, migration and homing. They home to the injured myocardium when administered intravenously (IV) to a wild type male rat subjected to MI. Methods: This model was created in 6-week-old Brown-Norway Rats. Rats were subjected to an anterior myocardial Infraction (MI) by permanent LAD ligation. The rats were treated with nMSCs (1^10 6 cells/Kg, 5^10 6 cells/Kg and 10^10 6 cells/Kg) along with placebo and sham, which are delivered intravenously by tail vein injection. Rats are once again treated with nMSCs/placebo 4 days after MI. Baseline echocardiography is performed 24 hours after MI. Results: LVEF was significantly higher in the nMSC-treated group than in the placebo group. Other parameters, including fractional shortening (FS) and decreased end-systolic volume (ESV), were also significantly improved when compared with the placebo group, and other LV functional parameter, including cardiac output/body weight and posterior wall thickness tended towards improvement of remodeled heart. Conclusions: Twice intravenous administration of nMSCs for MI attenuate the progressive deterioration of left ventricle and adverse remodeling of rat heart.

Stem Cell Therapy: A Promising Approach in Treatment of COVID 19

2020 ◽  
Vol 15 ◽  
Author(s):  
Bahareh Abbaspanah ◽  
Saeid Abroun ◽  
Morteza Zarrabi ◽  
Ashkan Mozdgir ◽  
Mohammad Mollanouri
Keyword(s):  
Stem Cells ◽  
Clinical Trials ◽  
Mesenchymal Stem Cells ◽  
Stem Cell ◽  
Global Health ◽  
Clinical Outcome ◽  
Cell Therapy ◽  
Stem Cell Therapy ◽  
Antiviral Treatment ◽  
Health Crisis

: COVID-19 pandemic is a global health crisis in the 21st Century. There are currently no approved vaccine and no particular antiviral treatment for coronavirus disease. As COVID-19 has had a broad range of illnesses, it is necessary to find a safe and effective therapeutic method for COVID-19. An attractive approach for treating COVID-19 is cell therapy. Cell therapy aims to inject new and healthy stem cells into a patient’s body, to repair the damaged cells and tissues. Stem cell therapy is one of the most studied and important approaches in treatment of COVID-19 these days. The significant clinical outcome was observed by the adoptive transfer of stem cells, specifically mesenchymal stem cells. This study reviews the characteristics of stem cells and clinical trials which uses stem cells in treating COVID-19.

Sign in / Sign up

Export Citation Format

Share Document